Molecular Partners Ag ADR (MOLN) Stock Price, Quote & News

Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting t...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 44 755 77 00

Fax: 41 44 755 77 07

Website: www.molecularpartners.com

Address:

Wagistrasse 14, Schlieren, Switzerland

HugeRocketTraders Mar. 16 at 5:07 PM

$MOLN resumed form the halt?

0 · Reply

erevnon Mar. 16 at 11:21 AM

HC Wainwright & Co. reiterates Molecular Partners $MOLN at Buy and maintains the price target at https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

RadioIsotope25 Mar. 13 at 4:32 PM

Clarity = $1 billion mkt cap $RADX $CATX $MOLN $ATNM $CLRB

0 · Reply

StocktwitsEarnings Mar. 12 at 10:41 PM

$MOLN Q4 '25 Earnings Results & Recap For the full year 2026, Molecular Partners expects total operating expenses of CHF45M, including approximately CHF6M in non-cash effective costs for share-based payments, IFRS pension accounting, and depreciation.

0 · Reply

6GodEnergy Feb. 27 at 6:23 PM

”@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of the traders on this platform. If you’re not paying attention yet, you’re missing out. Go give him a follow it’s completely free and only takes a second 💎 $EP $PNTG $LIMN $MOLN ^} on watch.

0 · Reply

OfficialStocktwitsUser Feb. 22 at 10:08 PM

$MOLN RSI: 75.00, MACD: 0.1742 Vol: 0.31, MA20: 4.51, MA50: 4.36 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

briefingcom Feb. 2 at 12:44 PM

$MOLN: Molecular Partners AG presents first imaging and dosimetry data for DLL3-targeting radiotherapy MP0712 at TWC 2026 https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260202051144MOLN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

BillionerOfKing Jan. 30 at 12:55 PM

$MOLN Current Stock Price: $4.15

0 · Reply

DARKP00L Jan. 27 at 1:17 PM

$MOLN

0 · Reply

DARKP00L Jan. 27 at 11:18 AM

$MOLN 06:16 on Jan. 27 2026 HC Wainwright & Co. Initiates Coverage On Molecular Partners with Buy Rating, Announces Price Target of $13 #tradeideas

0 · Reply

Molecular Partners Reports Highlights and Financial Results for Full Year 2025

Feb 26, 2026, 1:00 AM EST - 18 days ago

Market Cap	170.38M
Revenue (ttm)	5.65M
Net Income (ttm)	-61.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,086.55%
Debt to Equity Ratio	0.00

Volume	10,430
Avg Vol	4,430
Day's Range	N/A - N/A
Shares Out	40.38M
Stochastic %K	10%
Beta	1.03
Analysts	Strong Sell
Price Target	$10.62